William Lewis, serving as both Chair and Chief Executive Officer of INSMED Inc. (NASDAQ:INSM), finalized a significant transaction involving the company's equity on July 9, 2026. The executive sold 10,699 shares of INSMED common stock, generating a total proceeds value of $1,256,084. The liquidation occurred at share prices fluctuating between $116.01 and $118.80. At the time of this reporting, INSMED shares are trading at $115.61, a valuation that places the biopharmaceutical enterprise at a market capitalization of $25 billion.
In a simultaneous move, Mr. Lewis acquired an equivalent quantity of 10,699 shares through the exercise of stock options. The acquisition price for these options varied from $17.16 to $30.46 per share, culminating in a total transaction cost of $266,839. Both the sale and the option exercises were executed in strict adherence to a Rule 10b5-1 trading plan. This automated trading arrangement was established by Mr. Lewis on September 4, 2025. The underlying options followed a structured vesting schedule, wherein 25% of the grant vested upon the first anniversary of the grant date, with an additional 12.5% vesting every six months thereafter, continuing through the fourth anniversary of the grant date.
Following the completion of these transactions, Mr. Lewis's direct ownership stake in INSMED stands at 259,058 shares of common stock. This direct holding encompasses 141 shares obtained through the company's 2018 Employee Stock Purchase Plan. Furthermore, Mr. Lewis maintains an indirect ownership position of 233,924 shares held within a trust structure.
Concurrent with these executive transactions, Insmed has implemented structural changes within its leadership team. The company appointed Samuele Butera to the role of Senior Vice President and General Manager of Global Respiratory. This appointment positions Butera to lead Insmed's Respiratory Therapeutic Area, reporting directly to CEO Will Lewis. This strategic realignment underscores the company's focus on its core therapeutic divisions.
Simultaneously, the financial community has adjusted its outlook on Insmed's stock. Mizuho reduced its price target for Insmed shares to $192, citing market volatility as investors await the second-quarter results for the company's primary asset, Brinsupri. RBC Capital also lowered its price target to $195, following consultations with a key opinion leader and Insmed management regarding bronchiectasis treatments. Truist Securities adjusted its price target to $185, reflecting competitive risks and updates to their financial model following Insmed's first-quarter 2026 results. In contrast, Cantor Fitzgerald maintained its Overweight rating with a $235 price target, emphasizing the data outlook for Insmed's TPIP in pulmonary arterial hypertension.
According to InvestingPro analysis, INSMED appears overvalued at current levels based on Fair Value calculations. Investors can access a comprehensive Pro Research Report on INSM, one of 1,400+ available reports transforming complex data into actionable intelligence. The stock closed at $115.61, reflecting a decline of $2.65 or 2.24%. After hours trading showed a flat movement of $0.00.